Monte Rosa Therapeutics (GLUE) EPS (Weighted Average and Diluted) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly EPS (Weighted Average and Diluted) of -$0.45 in Q1 2026, up 18.18% quarter-over-quarter from -$0.55 in Q4 2025, and down 178.95% on a YoY basis from $0.57 in Q1 2025.
Monte Rosa Therapeutics (GLUE) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.45 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 178.95% year-over-year to -$0.45; the TTM figure through Mar 2026 stood at -$1.48 (down 1950.0% YoY), while the FY2025 annual figure was -$0.46, up 53.06% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.45 for Q1 2026 at Monte Rosa Therapeutics, up from -$0.55 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.57 in Q1 2025 to a low of -$0.71 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.4 across 5 years, with a median of -$0.53 in 2024.
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) slumped 472.73% in 2022, then jumped 207.55% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.63 in 2022, then advanced by 9.52% to -$0.57 in 2023, then soared by 140.35% to $0.23 in 2024, then plunged by 339.13% to -$0.55 in 2025, then increased by 18.18% to -$0.45 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.45 (Q1 2026), -$0.55 (Q4 2025), and -$0.33 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -0.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.45 |
| Dec 31, 2025 | -0.55 |
| Sep 30, 2025 | -0.33 |
| Jun 30, 2025 | -0.15 |
| Mar 31, 2025 | 0.57 |
| Dec 31, 2024 | 0.23 |
| Sep 30, 2024 | -0.29 |
| Jun 30, 2024 | -0.43 |
| Mar 31, 2024 | -0.53 |
| Dec 31, 2023 | -0.57 |
| Sep 30, 2023 | -0.70 |
| Jun 30, 2023 | -0.71 |
| Mar 31, 2023 | -0.65 |
| Dec 31, 2022 | -0.63 |
| Sep 30, 2022 | -0.58 |
| Jun 30, 2022 | -0.57 |
| Mar 31, 2022 | -0.51 |
| Dec 31, 2021 | -0.11 |
| Sep 30, 2021 | -0.43 |
| Jun 30, 2021 | -3.63 |